August 3, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3720
Attention: Irene Paik
| Re: | Nautilus Biotechnology, Inc. | |||||||
| Registration Statement on Form S-1 | ||||||||
| File No. 333-258100 | ||||||||
| Acceleration Request | ||||||||
| Requested Date: August 6, 2021 | ||||||||
| Requested Time: 4:00 P.M. Eastern Time | ||||||||
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Nautilus Biotechnology, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-l (File No. 333-258100) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Zachary B. Myers at (858) 350-2350.
| Sincerely, | |||||
| NAUTILUS BIOTECHNOLOGY, INC. | |||||
| /s/ Sujal Patel | |||||
| Sujal Patel | |||||
| Chief Executive Officer | |||||
| cc: | Anna Mowry | ||||
| Matthew Murphy | |||||
| Nautilus Biotechnology, Inc. | |||||
| Robert F. Kornegay | |||||
| Zachary B. Myers | |||||
| Wilson Sonsini Goodrich & Rosati, P.C. | |||||